liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Avdelningen för neuro- och inflammationsvetenskap. Region Östergötland, Hjärt- och Medicincentrum, Reumatologiska kliniken i Östergötland. Linköpings universitet, Medicinska fakulteten. Karolinska Institute, Sweden.
Helsingborgs Lasarett, Sweden; Skåne University Hospital, Sweden.
Karolinska Institute, Sweden.
Skåne University Hospital, Sweden.
Visa övriga samt affilieringar
2016 (Engelska)Ingår i: Annals of the Rheumatic Diseases, ISSN 0003-4967, E-ISSN 1468-2060, Vol. 75, nr 2, s. 356-361Artikel i tidskrift (Refereegranskat) Published
Resurstyp
Text
Abstract [en]

Objective To determine the relationship between changes in antibody levels towards citrullinated peptides derived from different candidate autoantigens and therapeutic outcome in early rheumatoid arthritis (RA). Methods Baseline and 3-month serum samples from 316 patients with early RA enrolled in the Swedish Farmacotherapy (SWEFOT) trial were analysed for antibodies against cyclic citrullinated peptides (CCP) and citrullinated peptides derived from vimentin (cVim), fibrinogen (cFib) and a-enolase (CEP-1). At 3-month follow-up, methotrexate monotherapy-inadequate responders were randomised to add-on therapy with sulfasalazine and hydroxychloroquine or infliximab. In these patients, anticitrullinated peptide antibodies (ACPA) were also assessed at 12 and 24 months. The proportion of antibody-positive patients and relative changes in antibody levels were compared across ACPA specificities and related to therapeutic response and radiographic progression. Results During the 2-year follow-up, the proportion of patients testing positive declined significantly regarding antibodies to cVim, cFib and CEP-1, while anti-CCP antibody occurrence remained stable over time. Turning anti-cVim antibody negative was most common, and anti-cVim antibody seroreversion during the first three months associated with significantly less 2-year radiographic progression compared with patients who remained positive. Median antibody levels of all tested ACPAs declined uniformly during initial methotrexate therapy and following response to add-on therapy, with no significant relation to treatment regimen or radiographic progression. Conclusions The influence of early antirheumatic therapy on ACPA seroreversions was markedly different across specificities, and early disappearance of anti-cVim antibodies associated with better radiological outcome. Thus, these data suggest that the disappearance of particular ACPA reactivities may be beneficial in early RA.

Ort, förlag, år, upplaga, sidor
BMJ PUBLISHING GROUP , 2016. Vol. 75, nr 2, s. 356-361
Nationell ämneskategori
Klinisk medicin
Identifikatorer
URN: urn:nbn:se:liu:diva-125298DOI: 10.1136/annrheumdis-2014-205698ISI: 000368955700006PubMedID: 25550338OAI: oai:DiVA.org:liu-125298DiVA, id: diva2:906397
Anmärkning

Funding Agencies|EU [FP7-Health-2010-261460, FP7-Health-2013-306029]; County Council of Ostergotland; Reinhold Sund Foundation; Swedish Society of Medicine; Swedish Rheumatism Association; Thelma Zoegas foundation in Helsingborg; Stiftelsen for Rorelsehindrade i Skane; Swedish Research Council; Strategic Foundations of Sweden (SSF)

Tillgänglig från: 2016-02-24 Skapad: 2016-02-19 Senast uppdaterad: 2017-11-30

Open Access i DiVA

fulltext(643 kB)205 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 643 kBChecksumma SHA-512
4de3ade3bae3295e39a38f886c56283435d061d088e990f1ee4c7b473a5fd77bee7f1d759e1440f9f29053eab6f3ac77191a93b1b1d4ff9e29e6f860219a8187
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Kastbom, Alf

Sök vidare i DiVA

Av författaren/redaktören
Kastbom, Alf
Av organisationen
Avdelningen för neuro- och inflammationsvetenskapReumatologiska kliniken i ÖstergötlandMedicinska fakulteten
I samma tidskrift
Annals of the Rheumatic Diseases
Klinisk medicin

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 205 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 1058 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf